Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...

Full description

Bibliographic Details
Main Authors: Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Format: Article
Language:English
Published: The Korean Association of Internal Medicine 2019-07-01
Series:The Korean Journal of Internal Medicine
Subjects:
daclatasvir
asunaprevir
hepatitis c, chronic
genotype 1b
real world
Online Access:http://www.kjim.org/upload/pdf/kjim-2017-368.pdf

Internet

http://www.kjim.org/upload/pdf/kjim-2017-368.pdf

Similar Items